Prostate Treatment Articles & Analysis
56 news found
Transcranial techniques are improving neurological diagnostics, while tumor tissue-based technology is revolutionizing cancer treatment, particularly in prostate cancer screening. In dermatology, new methods for treating benign epidermal lesions are emerging, alongside the development of drug-free therapies to enhance patient well-being. ...
This is like other cancers such as kidney and breast cancer, where treating the cancer while preserving the healthy tissue is the first consideration for treatment rather than full nephrectomy or mastectomy. Men with localized intermediate risk prostate cancer, meaning cancer has not spread from the prostate, would benefit most from focal ...
We are pleased to offer congratulations to Professor Jurgen Fütterer and his team at Radboud University Medical Centre in the Netherlands, for having successfully secured €3.8 million from the Dutch National Health Care Institute and ZonMw towards the ENFORCE trial, a fully funded Randomised Controled Trial for Focal Therapy which incorporates the NanoKnife System as a ...
Bayer is progressing novel research around its prostate cancer treatment darolutamide. The presentation highlights the synergistic anti-cancer effects of a PSMA (prostate-specific membrane antigen)-actinium-225 conjugate in combination with darolutamide in preclinical prostate cancer models. Darolutamide, which is jointly ...
ByBayer AG
BCR is defined as rising prostate-specific antigen (PSA) levels with a doubling time of after primary treatment (surgery or radiotherapy).1,2 Darolutamide is already approved under the brand name NubeqaTM for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of ...
ByBayer AG
Nubeqa is already approved in China for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease. ...
ByBayer AG
It is also approved for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) in a number of markets including the U.S and Japan. ...
ByBayer AG
Despite these treatments, a large proportion of men with mHSPC will eventually experience progression to metastatic castration-resistant prostate cancer (mCRPC), a condition with high morbidity and limited survival. ...
ByBayer AG
Despite these treatments, a large proportion of men with mHSPC will eventually progress to metastatic castration-resistant prostate cancer (mCRPC), a condition with high morbidity and limited survival. ...
ByBayer AG
It is also approved for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) in a number of markets including the U.S. ...
ByBayer AG
The study enrolled 478 patients who had received prior treatment with one or two lines of endocrine therapy, including a CDK 4/6 inhibitor. ...
“Now, as the new Chair in Translational Oncology, my laboratory will continue to work to develop ways to block the spread of cancer and improve the diagnosis and treatment of prostate cancer for men in Alberta and beyond.” The Edmonton-based Bird Dogs have passionately supported prostate cancer research for over a decade in memory ...
Prostatitis is a disease characterized by the presence of inflammation and/or infection localized in the prostate gland. ...
Upon relapse, when the disease will metastasize or spread, the disease is hormone-sensitive and androgen deprivation therapy (ADT) is the cornerstone of treatment. Current treatment options for men with metastatic hormone-sensitive prostate cancer (mHSPC) include hormone therapy, such as ADT, androgen receptor pathway inhibitors plus ADT or a ...
ByBayer AG
(TPEx: 6499), a Taiwan publicly traded medical device company, is pleased to announce positive interim results of the EXPANDER-1 Clinical Study for its flagship product the XFLO™ Expander System, an innovative, minimally invasive Benign Prostatic Hyperplasia (BPH) treatment solution. XFLO offers a reversible and office-based treatment ...
NEW YORK and SAN JUAN, Puerto Rico, Aug. 18, 2022 /PRNewswire/ -- miR Scientific, LLC announced the launch of national event #CanDoBlue to create awareness of the need for widespread prostate cancer testing during the 2022 Prostate Cancer Awareness Month (also known as "PCAM"). ...
“This approval reaffirms Bayer’s commitment to patients across different stages of prostate cancer, providing these eligible patients with a reliable treatment ...
ByBayer AG
BriaCell has been developing Bria-Pros™ as a potentially safe and effective personalized immunotherapy treatment for advanced prostate cancer. BriaCell’s Phase I/II trial in prostate cancer is expected to follow upon the completion of the manufacturing, testing, and the related regulatory filings. ...
The group is comprised of five experienced physicians with extensive experience using Cesium-131 monotherapy for permanent prostate brachytherapy who came together to form the advisory group. Commenting on the presentations, Isoray CEO Lori Woods said, “Long-term outcomes have demonstrated the significance of Cesium-131 brachytherapy for prostate cancer ...
The miR Sentinel™ Test assesses the risk of aggressive prostate cancer and is intended to aid in the clinical management of men >45 years of age at risk for prostate cancer. ...